![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
880kB | |
|
PDF (Supplemental Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
286kB |
| Item Type: | Article |
|---|---|
| Title: | Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
| Creators Name: | Kraus, S. and Klassen, P. and Kircher, M. and Dierks, A. and Habringer, S. and Gäble, A. and Kortüm, K.M. and Weinhold, N. and Ademaj-Kospiri, V. and Werner, R.A. and Schirbel, A. and Buck, A.K. and Herhaus, P. and Wester, H.J. and Rosenwald, A. and Weber, W.A. and Einsele, H. and Keller, U. and Rasche, L. and Lapa, C. |
| Abstract: | Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic (68)Ga-Pentixafor uptake in multiple myeloma (MM) with clinical parameters and to evaluate its prognostic impact. METHODS: Eighty-seven MM patients underwent molecular imaging with (68)Ga-Pentixafor-PET/CT. Splenic CXCR4 expression was semi-quantitatively assessed by peak standardized uptake values (SUV(peak)) and corresponding spleen-to-bloodpool ratios (TBR) and correlated with clinical and prognostic features as well as survival parameters. RESULTS: (68)Ga-Pentixafor-PET/CT was visually positive in all MM patients with markedly heterogeneous tracer uptake in the spleen. CXCR4 expression determined by (68)Ga-Pentixafor-PET/CT corresponded with advanced disease and was inversely associated with the number of previous treatment lines as compared to controls or untreated smouldering multiple myeloma patients (SUV(peak)Spleen 4.06 ± 1.43 vs. 6.02 ± 1.16 vs. 7.33 ± 1.40; (P<) 0.001). Moreover, reduced splenic (68)Ga-Pentixafor uptake was linked to unfavorable clinical outcome. Patients with a low SUV(peak)Spleen (<3.35) experienced a significantly shorter overall survival of 5 months as compared to 62 months in patients with a high SUV(peak)Spleen >5.79 ((P<) 0.001). Multivariate Cox analysis confirmed SUV(peak)Spleen as an independent predictor of survival (HR 0.75;P= 0.009). CONCLUSION: These data suggest that splenic (68)Ga-Pentixafor uptake might provide prognostic information in pre-treated MM patients similar to what was reported for diffusion-weighted magnetic resonance imaging. Further research to elucidate the underlying biologic implications is warranted. |
| Keywords: | Multiple Myeloma, 68 Ga-Pentixafor-PET/CT, CXCR4, Molecular Imaging, Spleen |
| Source: | Theranostics |
| ISSN: | 1838-7640 |
| Publisher: | Ivyspring International Publisher |
| Volume: | 12 |
| Number: | 13 |
| Page Range: | 5986-5994 |
| Date: | 8 August 2022 |
| Official Publication: | https://doi.org/10.7150/thno.75847 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
